## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.7% in lower entry zone (4.0-10.0%), top quartile (89th pct) cross-sectional ranking. Caution: MRS_5 (-0.1%) diverging from MRS_20, watch for reversal. Outperforming sector by 2.7%. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($551.45)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 2)

**1. What Ulta Beauty (ULTA)'s Upgraded 2025 Outlook and Loyalty Momentum Means For Shareholders**
- Source: Simply Wall Street | 20251214T050844 | Somewhat-Bullish | Relevance: 100%
- Ulta Beauty has reported strong third-quarter sales, raising its full-year 2025 guidance for net sales, operating margin, and EPS. This upgraded outlook is driven by robust sales growth, record loyalty engagement, and exclusive brand launches, reinforcing confidence in the company's operating model. The article discusses what this means for shareholders, the investment narrative, and potential risks like rising costs impacting margins.

**2. What Ulta Beauty (ULTA)'s Upgraded 2025 Outlook and Loyalty Momentum Means For Shareholders**
- Source: Simply Wall Street | 20251214T044127 | Bullish | Relevance: 100%
- Ulta Beauty recently reported strong third-quarter results and upgraded its full-year 2025 guidance, citing strong sales growth, record loyalty engagement, and exclusive brand launches. While this increased confidence in the company's operating model, investors should also consider the potential long-term pressures on profitability from rising costs in stores, wages, and benefits. Ulta’s narrative projects significant revenue and earnings growth by 2028, with a fair value estimate in line with its current price.

**3. Is It Too Late to Consider Ulta Beauty After Its Strong 2025 Share Price Rally?**
- Source: Simply Wall Street | 20251216T005057 | Bearish | Relevance: 100%
- Ulta Beauty's stock has seen significant gains, up 37.8% year-to-date and 120.5% over five years, reflecting growing confidence in the company. However, current valuations suggest Ulta (NASDAQ: ULTA) may be overvalued, scoring 1/6 on Simply Wall St's checks, with a Discounted Cash Flow analysis indicating it's about 55.3% overvalued and a PE ratio assessment also suggesting it's somewhat expensive. The article encourages investors to use "Narratives" on Simply Wall St to link business views to financial forecasts and fair value estimates.

**4. Class action claims Ulta misleads shoppers with false ‘free gift’ emails**
- Source: Class Action Lawsuits | 20251215T200925 | Bearish | Relevance: 100%
- An Ulta class action lawsuit alleges that the company sends emails with deceptive subject lines, falsely advertising "free gifts" and unqualified discounts without disclosing necessary conditions or exclusions. Lead plaintiff Veronica Repperger and three others claim these practices violate FTC guidelines and Washington state consumer protection laws. The lawsuit seeks declaratory and injunctive relief, along with statutory and treble damages for a class of consumers.

**5. Herbivore Debuts Exclusive Bodycare Collection and Partnership with Ulta Beauty**
- Source: PR Newswire | 20251215T120157 | Bullish | Relevance: 100%
- Herbivore, the prestige, plant-powered beauty brand, has announced a new partnership with Ulta Beauty, launching a 15-piece Body Collection exclusively for the retailer. This collection will be available in over 850 stores nationwide starting December 28, 2025, and online from December 21, 2025. This initiative, led by CEO Britany LeBlanc, marks a significant expansion for Herbivore into the bodycare category, leveraging Ulta Beauty's extensive reach to introduce plant-powered formulations to a wider audience.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |
| 2025-12-08 | TD Cowen | $725 | $600 | +21% |
| 2025-12-05 | DA Davidson | $650 | $625 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |
| 2025-12-08 | TD Cowen | up | Buy |
| 2025-12-05 | DA Davidson | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 13 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.52 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (13 raises, avg +6%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.4B |
| Beta | 0.87 |
| 52W Range | $309.01 - $611.90 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.52 |
| Forward P/E | 20.9 |
| Current P/E | 23.1 |
| YoY Growth | 10.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.6% to 6.7% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.5% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (4.25), confirming momentum. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.65% (CS: 90) | Strong |
| RSI_14 | 62.4 | Neutral |
| MACD Histogram | 4.25 | Bullish |
| vs SMA20 | 1.065x | Above |
| vs SMA50 | 1.095x | Above |
| vs SMA200 | 1.245x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $589.27
- **Stop Loss:** $551.45 (6.4% risk)
- **Target:** $646.00 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $18,267.37
- **Portfolio %:** 18.27%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.8% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*